|
Variable
|
Univariable analysis
|
Multivariable analysis
|
|---|
|
HR (95% CI)
|
P-value
|
HR (95% CI)
|
P-value
|
|---|
|
Treatment Arm
| | | | |
|
(A vs. B)
|
1.56 (0.60 to 4.16)
|
0.361
| | |
|
Age (>50 vs. ≤50)
|
1.45 (0.56 to 3.75)
|
0.441
| | |
|
IDC vs. ILC
|
1.34 (0.45 to 5.49)
|
0.462
| | |
|
Grade (3 vs1/2)
|
1.79 (0.67 to 4.81)
|
0.244
| | |
|
ER (+) vs. (−)
|
0.53 (0.21 to 1.35)
|
0.188
| | |
|
PR (+) vs. (−)
|
0.31 (0.11 to 0.89)
|
0.030
|
0.31 (0.10 to 1.19)
|
0.071
|
|
HER2 (+) vs. (−)
|
1.22 (0.45 to 3.26)
|
0.692
| | |
|
TN (yes) vs. (no)
|
1.75 (0.65 to 4.65)
|
0.267
| | |
|
Ki67 (High) vs. (Low)
|
1.47 (0.50 to 4.16)
|
0.480
| | |
|
pCR vs. non pCR
|
2.21 (0.88 to 6.64)
|
0.080
|
1.42 (0.08 to 2.32)
|
0.801
|
|
ALDH1 (+) vs. (−)
| | | | |
|
Baseline
|
1.10 (0.43 to 2.81)
|
0.831
| | |
|
Post NAC*
|
10.58 (1.65 to 14.68)
|
0.005
|
4.61 (1.30 to 23.00)
|
0.024
|
- ALDH1, aldehyde dehydrogenase-1; pCR, complete pathologic response; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; PR, progesterone receptor; TN, triple negative. *Post NAC, patients include ALDH1(−) as well as those with pCR.
